Endovascular Treatment and Outcomes for Femoropopliteal In-Stent Restenosis: Insights from the XLPAD Registry

Table 1

Baseline characteristics for femoropopliteal (FP) non-in-stent restenosis and in-stent restenosis (ISR) groups.

	Non-ISR (n = 2548)		ISR (n = 347)>		value
Age (years)	66.5 ± 9.8		67.2 ± 10.3		0.28
Gender
Male	1895	74.5%	237	68.30%	0.02
Female	649	25.5%	110	31.70%
Race
Caucasian (not Hispanic)	1809	73.0%	252	74.8%	0.120
African-American	435	17.5%	57	16.9%
Hispanic	202	8.15%	28	8.31%
Others (Asian, Native American, others)	34	1.37%	0	0.00%
Smoking
Within the past year	1248	49.6%	153	44.7%	0.24
>1 year ago	906	36.0%	136	39.8%
Never	364	14.5%	53	15.50%
Hypertension	2303	90.9%	313	90.7%	0.99
Diabetes mellitus	1368	54.4%	177	51.9%	0.41
Hyperlipidemia	2151	85.6%	299	87.9%	0.27
Chronic kidney disease	359	14.1%	42	12.10%	0.36
Coronary artery disease	1465	57.50%	198	57.1%	0.92
Heart failure	346	13.6%	33	9.51%	0.04
Prior nonfatal myocardial infarction	560	22.0%	62	17.9%	0.09
Prior stroke	209	8.2%	26	7.49%	0.73
Ankle-brachial index
ABI <0.9	1504	87.90%	195	87.1%	0.56
0.9 ≤ ABI <1.4	187	10.9%	28	12.50%
1.4 ≤ ABI	20	1.17%	1	0.45%
Rutherford class
CLI	933	36.6%	127	36.60%	1.000
IC	1615	63.4%	220	63.40%
Antiplatelet therapy	1852	89.4%	294	94.5%	0.01
Anticoagulation therapy	191	9.60%	36	11.9%	0.25
Statin	1537	60.3%	239	68.9%	0.003
ACEi/ARB	1265	61.9%	172	57.0%	0.12